4212
S. Ma et al. / Tetrahedron 70 (2014) 4208e4212
4.3. Allyl (1S,5S)-5-(tert-butyl)-1-methyl-2-oxocyclohexane-1-
CDCl3) d 157.3, 156.1, 136.4, 116.6, 48.2, 46.9, 45.1, 42.3, 41.9, 41.3,
carboxylate (2)
39.4, 38.6, 38.0, 35.5, 32.5, 28.2, 27.6, 26.9, 25.6, 23.6, 22.9, 21.0; IR
(neat film, NaCl) 3400, 3194, 2952, 2873, 1672, 1526 cmꢁ1; HRMS
25.1
1H NMR (300 MHz, CDCl3)
d
(dddd, J¼17.4 Hz, 10.5 Hz, 5.7 Hz,
m/z calcd for C25H43N3O [MþH]þ: 402.3484, found 402.3491; [
a]
D
5.7 Hz, 1H), 5.33 (dq, J¼17.4 Hz, 1.2 Hz, 1H), 5.23 (dq, J¼10.5 Hz,
1.2 Hz, 1H), 4.65 (dt, J¼5.7 Hz, 1.2 Hz, 2H), 2.45 (m, 2H), 2.21
(t, J¼12.6, 1H), 2.02 (m, 1H), 1.84 (dt, J¼13.5 Hz, 3.3 Hz, 1H), 1.59
þ29.73ꢀ (c 0.2550, hexane).
Acknowledgements
(m, 2H), 1.46 (s, 3H), 0.93 (s, 9H); 13C NMR (75 MHz, CDCl3)
d 210.5,
173.2, 132.2, 118.3, 66.0, 57.4, 41.9, 38.0, 37.0, 32.6, 27.6, 26.8, 21.0; IR
(neat film, NaCl) 2958, 2876,1740,1712,1459,1367,1249,1227,1165,
1112 cmꢁ1; HRMS m/z calcd for C15H24O3 [M]þ: 252.1726, found
252.1718.
The authors wish to thank NIH-NIGMS (R01GM080269), Abbott
the Gordon and Betty Moore Foundation (_100000936) and
Caltech for financial support. C.M.R. gratefully acknowledges the
Rose Hill Foundation for pre-doctoral funding. R.A.C. gratefully ac-
knowledges the support of this work provided by a fellowship from
the National Cancer Institute of the National Institutes of Health
(_100000002) under Award Number F31CA174359. Mr. Lawrence
Henling and Dr. Michael Day are gratefully acknowledged for X-
ray crystallographic structural determination. The Bruker KAPPA
APEXII X-ray diffractometer was purchased via an NSF CRIF:MU
award to the California Institute of Technology, CHE-0639094.
4.4. (trans)-2-Allyl-4-(tert-butyl)-2-methylcyclohexan-1-one
(3)
1H NMR (300 MHz, CDCl3)
2.38e2.23 (m, 4H), 2.03 (m, 1H),1.84 (m,1H),1.70 (m,1H),1.42e1.13
(m, 2H), 1.00 (s, 3H), 0.89 (s, 9H); 13C NMR (75 MHz, CDCl3)
216.0,
d 5.64 (m, 1H), 5.04 (m, 2H),
d
133.0,118.5, 48.2, 42.0, 40.1, 38.5, 32.4, 28.3, 27.7, 22.7; IR (neat film,
NaCl) 2962, 2870, 1709, 1366, 912 cmꢁ1; HRMS m/z calcd for
25.6
C
14H24O [M]þ: 208.1827, found 208.1825; [
a
]
D
ꢁ30.00 (c 1.08,
hexane).
4.5. (cis)-2-Allyl-4-(tert-butyl)-2-methylcyclohexan-1-one (4)
1H NMR (300 MHz, CDCl3)
5.77 (m, 1H), 5.03 (m, 2H), 2.50
Supplementary data
NMR spectra for compounds 1e4, as well as details on the ste-
reochemical assignment of compounds 1 and 2. Supplementary
data associated with this article can be found in the online version,
d
(m, 1H), 2.28 (m, 2H), 2.16 (m, 1H), 2.00 (m, 1H), 1.64 (m, 2H), 1.42
(m, 2H), 1.14 (s, 3H), 0.89 (s, 9H); 13C NMR (75 MHz, CDCl3)
d
216.2,
135.0, 117.9, 47.3, 43.3, 42.3, 38.9, 38.5, 32.5, 27.8, 27.7, 24.2; IR (neat
film, NaCl) 2963, 2870, 1709, 1366, 912 cmꢁ1; HRMS m/z calcd for
25.7
References and notes
C
14H24O [M]þ: 208.1827, found 208.1836; [
a
]
þ77.81ꢀ (c 0.105,
D
hexane).
2. Please see Supplementary data for more information.
3. The relative rate of consumption of starting material was determined by
comparing the negative slopes of Ln[b-ketoester] versus time for b-ketoesters 1
4.6. (E)-2-((2R,4S)-2-Allyl-4-(tert-butyl)-2-methylcyclohexyl-
idene)-N-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-
yl)hydrazine-1-carboxamide (5)
and 2.
1H NMR (300 MHz, CDCl3)
d
7.83 (br s, 1H), 6.08 (d, J¼9 Hz, 1H),
5.65 (m, 1H), 5.05 (m, 2H), 4.17 (m, 1H), 2.63 (m, 2H), 2.41 (m, 1H),
2.24 (m, 3H), 1.84 (m, 6H), 1.53 (m, 2H), 1.22 (s, 3H), 1.15 (app. dd,
J¼7.2 Hz, 1.0 Hz, 4H), 1.10 (s, 3H), 1.05 (s, 3H), 0.88 (d, 1H, J¼9.9 Hz),
0.85 (s, 9H); 13C NMR (75 MHz, CDCl3)
d 156.8, 156.0, 134.1, 117.8,
48.3, 48.2, 48.0, 47.1, 42.7, 41.9, 41.8, 39.8, 38.6, 38.1, 35.5, 32.5, 28.2,
27.6, 27.0, 25.0, 23.6, 22.6, 21.0; IR (neat film, NaCl) 3406, 3194,
3075, 2962, 1672, 1526 cmꢁ1; HRMS m/z calcd for C25H43N3O
[MþH]þ: 402.3484, found 402.3487; [
a
]
þ15.31ꢀ (c 0.2250,
25.0
D
ꢀ
CHCl3).
10. It should be noted that the percentages introduced in Fig. 7 are normalized to
100, and that the actual yield of the reaction of 93%. Unreacted starting material
or non-selective protonation products are assumed to account for the re-
maining 4R-t-Bu isomer absent from the allylic alkylation product mixture.
4.7. (E)-2-((2R,4R)-2-Allyl-4-(tert-butyl)-2-methylcyclohexyl-
idene)-N-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3
yl)hydrazine-1-carboxamide (6)
1H NMR (300 MHz, CDCl3)
d
8.42 (br s, 1H), 6.08 (d, J¼9 Hz, 1H),
5.94 (m, 1H), 5.04 (m, 2H), 4.17 (m, 1H), 2.71 (m, 2H), 2.37 (m, 3H),
1.91 (m, 5H), 1.55 (m, 3H), 1.21 (s, 3H), 1.12 (d, J¼7.5, 3H), 1.10 (s, 3H),
1.04 (s, 3H), 0.87 (d, J¼9.9 Hz, 1H), 0.84 (s, 9H); 13C NMR (75 MHz,